MedTrace Logo

CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

NCT03517176 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-08-28

No results posted yet for this study

Summary

CEND-1, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

Conditions

Interventions

DRUG

CEND-1

CEND-1 will be provided as concentrate for solution to be administered via IV injection.

DRUG

Nab-paclitaxel

Nab-paclitaxel will be provided as solution to be administered via IV infusion.

DRUG

Gemcitabine

Gemcitabine will be provided as solution to be administered via IV infusion.

Sponsors & Collaborators

  • Lisata Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-31
Primary Completion
2020-06-19
Completion
2020-06-19

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03517176 on ClinicalTrials.gov